ABN Newswire -- Australian regenerative medicine company, Mesoblast Limited, today announced that it has received clearance from the United States Food and Drug Administration (US FDA) for a Phase 2 clinical trial of its allogeneic or “off-the-shelf” adult stem cells in minimally invasive lumbar spinal fusion surgery.
